Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, and.
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Natl Compr Canc Netw. 2019 Sep 1;17(9):1135-1141. doi: 10.6004/jnccn.2019.7344.
Small bowel adenocarcinoma (SBA) is a rare cancer that has been treated similarly to colorectal cancer (CRC) in the advanced setting. Incidence has been increasing as detection efforts have been improving for these challenging-to-diagnose tumors, but patients frequently experience prolonged nonspecific symptoms due to delayed diagnosis. As a result of such delays and likely due to variant biology, patient outcomes for SBA are inferior to those for CRC at all stages of diagnosis. Recent molecular studies highlight the genomic differences underpinning these tumors and suggest new future pathways for treatment, distinct from CRC.
小肠腺癌 (SBA) 是一种罕见的癌症,在晚期的治疗方法与结直肠癌 (CRC) 相似。随着对这些难以诊断的肿瘤的检测工作的不断改进,其发病率一直在上升,但由于诊断延误,患者经常出现长期的非特异性症状。由于这种延误,可能由于生物学的变异,SBA 患者的预后在诊断的所有阶段都不如 CRC。最近的分子研究强调了这些肿瘤的基础基因组差异,并为治疗提供了新的未来途径,与 CRC 不同。